PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of cancer affecting the pancreas. With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts. A recent report from BioSpa ...

EonerenIntroduction Some people on Wall Street are so powerful that whenever they are interviewed, people drop everything to hear what they have to say. One of these people is JPMorgan (JPM) CEO Jamie Dimon, who has a reputation as one of the best banking CEOs in modern history. Since January 1, 2000, his bank has returned 681%, beating the S&P 500 by roughly 220 points. That's a huge deal as it includes the Great Financial Crisis, the pandemic, and last year's banking woes. Data by YChartsWith that sai ...

-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a memb ...

Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern medicine. Some biotech companies can face volatility as their popularity largely depends on pipeline updates. But some have proven more resilient than others.These three biotech stocks are some of the sector’s most consistently performing stocks. They produce medicines in both the pharma and biotech classes. Despit ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

This company offers growth, high yield, and dividend growth.When it comes to investing, I often look for companies that generate strong amounts of free cash flow (FCF), and companies that can grow their FCF. One company that has proven that over the years is AbbVie (ABBV -0.99%). I often refer to it as The Investor's Trifecta, offering growth potential, high yield, and solid dividend growth.Check out this short video to learn more, consider subscribing to the channel, and check out the special offer in the ...

This pharma giant just made a smart strategic acquisition.There are plenty of reasons to buy a leading biopharma business like AbbVie (ABBV -0.99%), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it could now become a prominent psychiatric-drug company.Though the area isn't traditionally in AbbVie's wheelhouse, there's reason to believe that its latest bet will turn out well for investors. Here's why.This new segment could be incredibly valuableOn May ...

文章核心观点 - 股票市场存在周期性的下跌,即"熊市"和"修正"[1][2][3] - 熊市和修正通常持续时间较短,但随后的牛市通常持续时间较长[2][3] - 即使在下跌时期,也有一些表现良好的股票可以投资[4] 沃尔玛(Walmart) - 沃尔玛是在经济衰退时期表现良好的股票之一[5][6] - 沃尔玛在过去的市场崩溃中都表现出色,如2008-2009年金融危机和2001年互联网泡沫破裂[6] - 从1970年IPO至今,沃尔玛的总回报率达到462,000%[7] 亚马逊(Amazon) - 亚马逊在近期的市场修正和崩溃中表现出色,原因是其作为零售业的重要组成部分[9][12] - 亚马逊的业务从最初的图书销售发展到现在的多元化,包括推出Prime会员计划和开设杂货业务[10][11] - 从1997年IPO至今,亚马逊的总回报率达到188,000%[13] 艾伯维(AbbVie) - 艾伯维是从雅培(Abbott)分拆出来的制药公司,自2013年成立以来表现良好[14] - 艾伯维在2020年疫情期间的回报率超过27%,优于大盘[14] - 尽管艾伯维的核心产品Humira专利即将到期,但公司仍有强大的新药管线[15][16][17]

文章核心观点 - 尽管AbbVie的主要药物Humira在美国已经失去专利保护,但公司在2024年第一季度的收入增长仍然令人鼓舞[1][3][4] - 公司新药Rinvoq和Skyrizi的销售增长抵消了Humira销售下降的影响[5] - 公司计划以87亿美元收购Cerevel Therapeutics,这可能为公司的后期研发管线增添一款潜在的新药物[6] 公司表现 - 2024年第一季度收入同比增长0.7%,调整后每股收益下降6.1%至2.31美元[4] - Humira在美国的销售下降39.9%至18亿美元,但Rinvoq和Skyrizi的销售增长分别为59.3%和47.6%[5] - 公司目前股价对应2024年调整后每股收益的14.8倍,估值较为合理,同时股息收益率为3.7%[7]

文章核心观点 - 公司正在通过在炎症性肠病(IBD)领域的研究和创新,努力提高治疗标准,为患者带来更好的临床结果 [1][2] - 公司将在2024年消化系统疾病周(DDW)年会上,就其在克罗恩病和溃疡性结肠炎治疗方面的研究成果进行大量报告 [1][3][4][5][6][7] - 公司正在研究其两款药物risankizumab和upadacitinib在IBD治疗中的应用,包括在症状缓解、内镜改善和组织学改善等方面的疗效 [3][4][5][6][7] 根据目录分组总结 关于risankizumab - 公司正在评估risankizumab与ustekinumab在中重度克罗恩病患者中的疗效对比,包括症状改善、内镜改善和生物标志物改善等指标 [3][9] - 公司正在评估risankizumab在中重度溃疡性结肠炎患者中的疗效,包括达到无糖皮质激素治疗的临床、内镜和组织学缓解的情况 [4][5][9][10][11] 关于upadacitinib - 公司正在评估upadacitinib在中重度溃疡性结肠炎患者中的疗效,包括两年内达到无糖皮质激素治疗缓解的情况 [6] - 公司正在分析upadacitinib对IBD患者血脂谱的影响 [7] 行业概况 - IBD是一组特征为胃肠道慢性炎症的疾病,包括克罗恩病和溃疡性结肠炎 [68] - IBD是一种进行性疾病,会随时间恶化,并可能导致严重并发症或手术 [68][69] - IBD不仅给患者带来身体上的负担,也给他们的生活质量和经济状况带来很大影响 [69]